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AbstrACt
Introduction Conflicting results from multiple randomised 
trials indicate that the methods and effects of blood 
pressure (BP) reduction after acute intracerebral 
haemorrhage (ICH) are complex. The Blood pressure in 
Acute Stroke Collaboration is an international collaboration, 
which aims to determine the optimal management of BP 
after acute stroke including ICH.
Methods and analysis A systematic review will be 
undertaken according to the Preferred Reporting Items 
for Systematic review and Meta-Analysis of Individual 
Participant Data (IPD) guideline. A search of Cochrane 
Central Register of Controlled Trials, EMBASE and MEDLINE 
from inception will be conducted to identify randomised 
controlled trials of BP management in adults with acute 
spontaneous (non-traumatic) ICH enrolled within the first 
7 days of symptom onset. Authors of studies that meet 
the inclusion criteria will be invited to share their IPD. The 
primary outcome will be functional outcome according to 
the modified Rankin Scale. Safety outcomes will be early 
neurological deterioration, symptomatic hypotension and 
serious adverse events. Secondary outcomes will include 
death and neuroradiological and haemodynamic variables. 
Meta-analyses of pooled IPD using the intention-to-treat 
dataset of included trials, including subgroup analyses 
to assess modification of the effects of BP lowering 
by time to treatment, treatment strategy and patient’s 
demographic, clinical and prestroke neuroradiological 
characteristics.
Ethics and dissemination No new patient data will 
be collected nor is there any deviation from the original 
purposes of each study where ethical approvals were 
granted; therefore, further ethical approval is not required. 
Results will be reported in international peer-reviewed 
journals.
PrOsPErO registration number CRD42019141136.
IntrOduCtIOn
rationale
Acute treatments proven to alter the prog-
nosis of stroke due to spontaneous (non-trau-
matic) intracerebral haemorrhage (ICH) 
are limited. A 2014 Cochrane review that 
appraised the totality of evidence for blood 
pressure (BP) lowering within 1 week of 
acute stroke concluded that the supporting 
evidence was insufficient to make clear 
recommendations about this intervention, 
strengths and limitations of this study
 ► The Blood pressure in Acute Stroke Collaboration is 
an international collaboration with the prospective 
aim of pooling individual participant data (IPD) from 
randomised controlled trials (RCTs) of blood pres-
sure (BP) management in acute stroke, including 
intracerebral haemorrhage (ICH).
 ► Meta-analysis of IPD is regarded as the gold stan-
dard for synthesising evidence from multiple RCTs.
 ► This study aims to collect sufficient data to deter-
mine the optimal management of BP in acute ICH 
and will facilitate comparisons across subgroups 
according to patient characteristics, time to treat-
ment and treatment strategy.
 ► This study will identify associations of treatment-re-
lated haemodynamic parameters, which will inform 
future research.
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and the findings were similar for ischaemic stroke and 
ICH.1 In regard to ICH, several randomised controlled 
trials (RCTs) have focused on early intensive BP reduction 
and included participants with mild-to-moderate acute 
ICH in the hospital setting.2–4 Other trials commenced 
BP lowering in the prehospital period before diagnostic 
brain imaging, and by their nature included a mixture of 
ischaemic stroke and ICH patients, including more severe 
cases of ICH.5–7 Data from ICH cases are also available 
from RCTs, which used longer inclusion windows (up to 
48 hours).8–12 Furthermore, various agents and BP targets 
have been tested, and few trials considered prognostic 
implications of prestroke neuroimaging characteristics. 
Therefore, a substantial and varied body of evidence 
about BP lowering and outcome after acute ICH is avail-
able, but much of it is conflicting.13 
The Blood pressure in Acute Stroke Collaboration 
(BASC) is an international collaboration, which aims 
to prospectively pool individual participant data (IPD) 
from RCTs of BP control after acute stroke, including 
stroke due to ICH.14 15 IPD meta-analysis is consid-
ered the gold-standard for synthesising evidence from 
RCTs16 and, in this context, provides added value to 
meta-analyses of aggregate data17 by facilitating multi-
variable analyses of treatment effects and subgroup 
analyses according to time to treatment, treatment 
strategy used and baseline characteristics including 
neurological severity and haematoma volume, adjusted 
for confounding factors.
Primary objective
To determine the effect of BP lowering on clinical 
outcomes in patients with acute ICH and elevated BP.
secondary objectives
1. To determine the effect of BP lowering according to 
baseline patient clinical and neuroradiological char-
acteristics, BP lowering strategy and timing of the 
intervention.
2. To determine the effect of BP lowering on radiological 
outcomes.
3. Where sufficient data are available, report associations 
of on-treatment haemodynamic parameters, adjusted 
for known confounders.
MEthOds And AnAlysIs
This systematic review and IPD meta-analysis will be 
performed in accordance with the recommendations 
made by the methods group of the Cochrane Collab-
oration (http:// ipdmamg. cochrane. org/ resources) 
and the UK Medical Research Council Network of 
Hubs for Trials Methodology Research.18 The protocol 
has been developed in accordance with the Preferred 
Reporting Items for Systematic reviews and Meta-Anal-
yses of IPD checklist19 and has been registered with the 
international prospective register of systematic reviews, 
PROSPERO.20
Patient and public involvement
This protocol was developed without the involvement of 
patients or members of the public.
Eligibility criteria
Study designs
RCTs of BP reduction during the acute phase (<7 days) of 
stroke will be included.
Participants
Adults (aged >18 years) with spontaneous ICH will be 
included. For trials including both ICH and ischaemic 
stroke, we will include only patients with ICH. Partic-
ipants with secondary ICH (eg, due to trauma, tumour 
or vascular malformation) will be excluded. Uncertainty 
about an individual trial’s eligibility criteria will be clari-
fied with the appropriate investigator.
Interventions
Trials that involve interventions that lower BP including 
oral, sublingual, transdermal and intravenous agents and 
single or combination therapy will be considered.
Comparators
Control groups will typically be managed with 
placebo or according to contemporaneous guideline 
recommendations.
Outcomes
Trials that report data on death and functional outcome 
using the seven-level modified Rankin Scale (mRS, where 
scores range from 0=no symptoms to 5=severe disability 
and 6=death) at 90 days will be included. Where outcome 
data are not reported this way, the nearest time point 
or suitable surrogate will be considered. Data regarding 
other outcomes (survival, quality of life, cognitive func-
tion), serious adverse events (SAEs), haematoma charac-
teristics (growth, final volume, mass effect, oedema) and 
haemodynamic measures will be sought.
Setting
There will be no restrictions on the type of setting.
Language
There will be no language restriction.
Information sources
Trials will be sought using electronic searches of Cochrane 
Central Register of Controlled Trials, EMBASE and 
MEDLINE and in the reference lists of published system-
atic reviews and ad hoc reviews. Ongoing or unpublished 
trials will be identified using  ClinicalTrials. gov and the 
WHO’s International Clinical Trials Registry Platform.
search strategy
Searches of the above bibliographic databases will be 
conducted using a combination of search terms relevant 
to the proposed study (online supplementary material 1). 
Databases will be searched from inception to the present. 
The search strategy will be enhanced through searches of 
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the existing BASC reviews, the authors’ publication data-
bases and reference lists in identified articles.
selection process
All titles and abstracts will be screened against the eligi-
bility criteria by TJM and ZKL. Any disagreements will be 
settled by an adjudicator, PMB. The principal investiga-
tors of eligible studies will be invited to participate in the 
collaboration.
data management
Data sharing
Investigators of eligible studies will receive a written invi-
tation to share their IPD. To ensure transparency, collabo-
rators sharing data with BASC will be asked to sign a data 
transfer agreement for the predefined and appropriate 
use of their data according to this protocol.
Data checking
Initial internal analyses will compare data from each 
trial with their published results to ensure that data are 
complete and transferred without error: this will include 
checking the primary outcome and all baseline variables 
or secondary outcomes relevant to the proposed analyses. 
The integrity of all data will be checked and any queries 
resolved with individual trial investigators.
Data merging
Datasets obtained from collaborating studies will be 
combined to form a new master dataset, which will 
include a variable to indicate the original study.
Confidentiality, data storage and handling
Each collaborator will deidentify their dataset to ensure 
no patient identifiable information is transferred. Data 
will be shared electronically and stored on password-pro-
tected, encrypted hard disks in a locked room, with daily 
backup facilitating disaster recovery.15 Data will not be 
shared with anyone outside the collaborating group.
data items
Variables that will be requested from participating investi-
gators are listed in online supplementary material 2, and 
can be outlined as follows:
 ► Trial information
 ► Demographics
 ► Medical history
 ► Medications at the time of admission
 ► Baseline clinical variables
 ► Baseline neuroimaging characteristics of the acute 
ICH and prestroke features (leukoaraiosis, atrophy, 
prior stroke lesions)
 ► BP treatment and all trial BP data
 ► Clinical and radiological outcome data
study outcomes
Primary outcome
The preferred primary effect variable will be functional 
outcome defined by the ordinal distribution of mRS 
scores at the end of trial follow-up (usually 3 months).
Secondary outcomes
(1) Death and dependency (3–6 on the mRS); (2) death 
or severe disability (4–6 on the mRS); (3) all-cause death; 
and (4) health-related quality of life (mobility, self-care, 
usual activities, pain or discomfort and anxiety or depres-
sion), as assessed with the use of the European Quality of 
Life–5 Dimensions questionnaire.
Safety outcomes
(1) Early neurological deterioration (as defined by each 
individual trial); (2) symptomatic hypotension (as defined 
by each individual trial); and (3) other SAEs, as defined 
by trial, to include fatal, non-fatal and treatment-related 
SAEs (including renal SAEs).
Radiological outcomes
(1) Haematoma growth, both absolute and proportional, 
will be studied where these data were collected by indi-
vidual trials and is based on central measurements from 
semiautomated planimetric21 or ABC/222 methods; (2) 
other imaging outcomes (eg, perihaematomal oedema) 
will be included in supplemental analyses.
Subgroup analyses
Where adequate data are available, heterogeneity in the 
effect of BP lowering on outcomes will be assessed in the 
following subgroups to determine whether any effects of 
BP lowering are moderated by patient’s characteristics 
and BP lowering treatment (agent, target, timing or place 
of delivery):
 ► Baseline characteristics: demographic (age, sex, 
region), clinical (stroke severity, baseline systolic 
BP, prestroke antihypertensive drug use, prestroke 
antithrombotic use) and radiological parameters 
(ICH volume, pre-stroke characteristics).
 ► BP lowering strategy: intervention/class-based treat-
ment, BP target-based treatment.
 ► Timing of intervention: <2 hours, 2–6 hours, 
6–48 hours and >48 hours after onset of ICH.
 ► Type of trial: prehospital versus hospital and ICH only 
versus mixed.
Associations of calculated BP parameters and primary outcome
Once all data have been pooled, an assessment of the new 
dataset will be made with a view to use trial BP and heart 
rate measures to calculate important BP lowering haemo-
dynamic parameters, a number of which have been associ-
ated with outcome after ICH.23–26 The aim is to determine 
the prognostic significance of these calculated variables, 
adjusted for all known confounders, and present these 
data in secondary analyses.
risk of bias in individual studies
Two investigators (TJM and ZKL) will assess each included 
study for bias using the Cochrane Collaboration tool 
(http:// methods. cochrane. org/ bias/ assessing- risk- bias- 
included- studies). A judgement of bias will be made 
according to six domains: selection, performance, detec-
tion, attrition, reporting and ‘other’ biases. Disagreements 
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will be resolved with discussion or by involving PMB if 
necessary. Any uncertainties about trial design, conduct or 
analysis methods will be clarified with the individual trial’s 
investigators.
statistical analyses
Primary analyses will be performed using the intention-
to-treat dataset from each trial with a one-stage approach. 
Patients without available data or where the above proce-
dure for missing data cannot be applied will be excluded 
from these analyses.
Online supplementary material 3 contains table and 
figure shells that will be used to present our findings. 
In summary, descriptive analyses will be undertaken in 
order to identify key similarities and differences between 
trials, therefore providing context for interpretation 
of between-trial differences in outcomes. Data will be 
described as mean (SD) or median (IQR) for continuous 
data or frequency (percentage) for categorical data, and 
chi-squared or Kruskal-Wallis tests will be used to make 
comparisons.
Generalised linear mixed models will be used with covari-
ates (age, sex, ICH severity, time from onset to randomis-
ation), and the source trial added as a random effect to 
account for clustering. For completeness, analyses will 
also be performed unadjusted. Results from binary and 
ordinal analyses (eg, death, dichotomised outcomes of mRS 
scale, neurological deterioration, SAEs, full-scale mRS) 
will be presented as ORs with 95% CIs. The proportional 
odds assumption will be checked before ordinal analyses 
of outcomes on the mRS are undertaken. If the propor-
tional odds assumption is not met, various standard binary 
cut-points for poor outcome on the mRS will be used. 
Continuous or pseudocontinuous outcome analysis results 
will be presented as mean difference with 95% CI. For time-
to-event outcomes, a Cox proportional hazards model will 
be used to determine HRs with the source trial added as a 
random effect, and the assumption of proportional hazards 
will be tested.
Additional analyses will be performed in prespecified 
subgroups, with an interaction term in models to test 
heterogeneity.
Sensitivity analyses using a two-stage approach will be 
conducted to test the robustness of our primary results and 
will permit (1) inclusion of aggregate data from studies 
where IPD cannot be obtained to address the issue of data 
availability bias27 and (2) assessment with and without studies 
deemed to have high risk of bias.
An assessment of heterogeneity will be performed 
before data pooling using the Cochrane Q statistic and 
I2 statistic.
An assessment of publication bias will be made by visual 
inspection for funnel plot asymmetry (with and without 
studies where IPD is obtained) and with Egger’s regression 
test. The Grades of Recommendation, Assessment, Develop-
ment and Evaluation28 will be used to evaluate the quality of 
the synthesised evidence.
EthICs And dIssEMInAtIOn
Ethical approval for the original studies was sought and 
is documented elsewhere. No new patient data will be 
collected nor is there any deviation from the original 
purposes of each study; therefore, further ethical approval 
is not required. Results from this study will be published in 
international peer-reviewed journals. All publications from 
this work will be in the name of the BASC Investigators.
dIsCussIOn
The proposed study will use pooled IPD from RCTs to 
address the role of BP management in the acute phase of 
ICH. Conflicting results from multiple clinical trials indi-
cate that BP reduction is not a straightforward question of 
whether to treat or not. Rather, the problem is complex and 
needs to take account of patient characteristics, physiolog-
ical parameters including baseline BP, stroke severity, the 
timing of treatment, strategy and class of antihypertensive 
agent, route of administration and dose or target BP.
Elevated baseline systolic BP is associated with haema-
toma expansion,29 perihaematomal oedema formation30 
and increased case fatality.31 There is evidence from some 
studies that intensive lowering of BP reduces haema-
toma enlargement,32 is safe and tolerable2 3 and does not 
alter cerebral blood flow.33 Current guidelines recom-
mend lowering BP early in the course after ICH and that 
targeting a goal of systolic BP <140 mm Hg is probably 
safe in patients presenting with an SBP of 150–220 mm 
Hg.34 35 Nevertheless, other studies reported no effect 
of BP reduction on haematoma enlargement,3 4 and the 
neutral findings of the ATACH-II trial4 emphasise that all 
published data need to be appraised together.
Although guidelines recognise the need for very early 
treatment, none address the role of prehospital BP reduc-
tion. Further evidence is also required to confirm associ-
ations between key haemodynamic variables, such as BP 
variability,23 with poor outcome. Furthermore, the influ-
ence of patient’s characteristics that are present prior to 
ICH on BP lowering interventions is unknown, although 
these same variables are known to worsen long-term 
recovery; these include having a prior stroke, white matter 
lesions or brain atrophy. The proposed investigation aims 
to provide definitive evidence on these important issues.
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